Bracco Imaging – with FY20 revenues and EBITDA of €1,199m and €260m (22% margin)- is engaged in the development and distribution of imaging agents applied for X-Ray, MRIs and Nuclear Medicine. The Group has a balanced geographic presence across North America (52% of 2020 revenues), Europe (28%), RoW (20%, mostly China and Japan), and it is entirely controlled by the founder family through Bracco S.p.A. 

On 29 September 2021, Bracco Imaging signed a new 5-year ESG-linked term loan in club deal format, for an amount of €450m, intended to refinance the €440m syndicated term loan set up in Jul-19 to support the acquisition of Blue Earth Diagnostic (UK-based molecular imaging diagnostics company).

Mediobanca participated to the transaction as Mandated Lead Arranger alongside the other relationship banks of the Group.
The transaction consolidates Mediobanca successful business relationship with Bracco and its founder family built over the last years.